Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

OptimizeRx (OPRX) Debt to Equity (2019 - 2025)

Historic Debt to Equity for OptimizeRx (OPRX) over the last 6 years, with Q3 2025 value amounting to $0.23.

  • OptimizeRx's Debt to Equity fell 2542.46% to $0.23 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.23, marking a year-over-year decrease of 2542.46%. This contributed to the annual value of $0.28 for FY2024, which is 202.86% down from last year.
  • Latest data reveals that OptimizeRx reported Debt to Equity of $0.23 as of Q3 2025, which was down 2542.46% from $0.24 recorded in Q2 2025.
  • OptimizeRx's Debt to Equity's 5-year high stood at $0.31 during Q3 2024, with a 5-year trough of $0.23 in Q3 2025.
  • For the 3-year period, OptimizeRx's Debt to Equity averaged around $0.28, with its median value being $0.28 (2023).
  • Its Debt to Equity has fluctuated over the past 5 years, first plummeted by 202.86% in 2024, then tumbled by 2542.46% in 2025.
  • Quarter analysis of 3 years shows OptimizeRx's Debt to Equity stood at $0.29 in 2023, then decreased by 2.03% to $0.28 in 2024, then fell by 18.06% to $0.23 in 2025.
  • Its Debt to Equity stands at $0.23 for Q3 2025, versus $0.24 for Q2 2025 and $0.28 for Q1 2025.